REGENEREX PHARMA, INC.

RGPXdata completeness 63%15 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'epsDiluted'

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	$1,775¹	—	—	—	—
Net income	−$353,752²	−$195,591³	−$137,330⁴	−$3.54M⁵	−$2.53M⁵
Operating cash flow	−$62,652⁶	−$69,922⁷	−$76,164⁸	−$457,548⁹	−$1.63M⁹
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	—	—	—	$184,232¹⁰	—
Cash & equivalents	$6,902¹¹	$2,640¹²	$1,135¹³	$372¹⁴	$653,025¹⁴
Diluted shares	127.1M	183.4M	277.1M	277.7M	278.7M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$0.15

your share of equity

Profit it earned you last year

−$0.09

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on −$0.15 of net worth that earned you −$0.09 last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 5y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+119% shares · 5y

Share count is up 119% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts